“Tripling the footprint of EAG’s current cell bioassay laboratory, the expanded labs will include the addition of cell culturing incubators, as well as new instrumentation to increase capacity and assay throughput, enabling EAG to simultaneously support multiple development programs,” Siddhartha Kadia, President and CEO of EAG, said.
The scientific services company is also planning to increase its staff of biopharmaceutical scientists by up to 35% over the next several months.
The lab is being built at the Columbia, Missouri facility and will be divided into multiple suites to minimize cross-contamination of cell lines.
Additionally, Amanda Halford has been appointed as senior vice president, life sciences, in addition to her role as chief commercial officer. In her new role, Halford will be responsible for driving growth in EAG’s commercial and laboratory operations.
“Over the last year, we have made great strides as a company, including the unification of many small businesses under one brand. Amanda has been a critical part of that by putting in place a commercial strategy that leverages the scale and expertise of our entire organization,” said Kadia.